Vertex holds a dominant position in the cystic franchise (“CF”) market. Its CF sales continue to grow, driven by higher sales of Trikafta/Kaftrio in younger age groups. Vertex’s CF product ...

The past decade has been a game-changing one for Vertex Pharmaceuticals (NASDAQ: VRTX). The biotech won approval for its first cystic fibrosis (CF) drug -- Kalydeco -- back in 2012 and has since ...

KING OF PRUSSIA, Pa., March 11, 2025 (GLOBE NEWSWIRE) -- Vertex, Inc. (NASDAQ: VERX) today announced that it will host an Investor Day on Wednesday, March 19, in Philadelphia, PA. The event will ...

Vertex has stepped up its interest in kidney disease over the past year, moving inaxaplin into a phase 2/3 AMKD trial at the start of April and inking a $4.9 billion deal to buy Alpine Immune ...

Vertex Pharmaceuticals Inc.’s new non-opioid painkiller is being placed on a tier that means it might be costlier than other pain treatments on UnitedHealth Group Inc.’s approved drug lists.

To that end, Florida Tech has relaunched the underutilized Center for Advanced Manufacturing and Innovative Design as Vertex, a new "applied innovation hub." Rather than function as a traditional ...

Vertex has doubled down on cell-based therapies for type 1 diabetes (T1D), buying ViaCyte in a $320 million deal that it says will accelerate development of its own candidate VX-880. The deal has ...

In its fourth quarter 2024 investor letter, Parnassus Core Equity Fund emphasized stocks such as Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX). Vertex Pharmaceuticals Incorporated (NASDAQ ...

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF ...

RBC Capital notes that the clinical review documents associated with Sector Perform-rated Vertex Pharmaceuticals (VRTX)’ recent approval of Journavx were posted to FDA’s online repository ...

Three people with type 1 diabetes who received Vertex Pharma’s islet cell therapy VX-880 have been able to come off insulin altogether within a year, raising the prospect of a life without ...